To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
- Sponsor
- Rep. Murphy, Gregory F. [R-NC-3]
- Committees
- Ways and Means Committee (primary)
- Last action
- Feb 21, 2025
Bottom line
This bill extends the market exclusivity period for small-molecule drugs by four years before they are subject to federal price negotiation, potentially impacting drug development incentives and consumer costs.
What it actually does
This bill amends title XI of the Social Security Act to extend the period before small-molecule drugs become eligible for price negotiation under the Drug Price Negotiation Program. Specifically, it changes the eligibility window from 7 years to 11 years, aligning it with the period currently applicable to biologic drugs. The amendment is set to take effect as if it were part of the original enactment of Public Law 117-169, which established the negotiation program.
Proponents argue
Supporters argue that extending the negotiation eligibility period for small-molecule drugs to 11 years would incentivize pharmaceutical companies to invest more in research and development for these drugs. They contend that the current 7-year period is insufficient to recoup R&D costs, especially given the high failure rates and lengthy development timelines for new medications. Equalizing the period with biologics would create a more level playing field and foster innovation.
Opponents contend
Opponents argue that extending the negotiation period would delay access to lower-cost drugs for consumers and increase federal spending on prescription medications. They contend that the current 7-year period, established by the Inflation Reduction Act, is a crucial step towards reining in drug prices and that extending it would undermine efforts to make drugs more affordable, prioritizing pharmaceutical profits over patient access.
The bill text is extremely short and can be read in under a minute, making it highly accessible for immediate understanding of its direct change.
Section 1. Equalizing the Negotiation Period Between Small-Molecule and Biologic Candidates Under the Drug Price Negotiation Program.
Extension of Drug Price Negotiation Eligibility for Small-Molecule Drugs
This provision modifies the Social Security Act to change the eligibility criteria for small-molecule drugs under the Drug Price Negotiation Program. Currently, these drugs become eligible for negotiation 7 years after their approval. This bill extends that period to 11 years, matching the current eligibility period for biologic drugs. This means pharmaceutical companies would have an additional four years of market exclusivity for small-molecule drugs before their prices could be negotiated by the federal government.
Supporters argue
Supporters argue that this extension is crucial for fostering innovation in small-molecule drug development. They contend that the current 7-year period is insufficient for companies to recoup the substantial R&D investments, especially when compared to biologics which have an 11-year period. This change would provide a more equitable and robust incentive structure, leading to more new treatments for patients.
Critics contend
Opponents argue that this provision would significantly undermine the intent of the Inflation Reduction Act to lower drug costs for seniors and taxpayers. They assert that extending exclusivity by four years would delay much-needed price relief, allowing pharmaceutical companies to maintain high prices for a longer duration, thereby increasing healthcare costs for both individuals and federal programs like Medicare.
Tradeoffs
The provision navigates the tension between incentivizing pharmaceutical innovation through longer market exclusivity and ensuring timely access to affordable medications for patients and federal healthcare programs. It balances the industry's desire for greater returns on investment against the public's demand for lower drug prices.